Other Events ·
Galmed Pharmaceuticals Ltd. received notification from Nasdaq granting an additional 180-day compliance period to…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. received notification from Nasdaq granting an additional 180-day compliance period to regain adherence to the minimum $1 bid price per share requirement, extending the deadline to January 25, 2027. The company initially failed to maintain this threshold for 30 consecutive trading days starting January 29, 2026, and missed its first compliance window ending July 28, 2026. To restore good standing, Galmed must achieve a closing bid price of at least $1 per share for ten consecutive trading days before the new deadline. This company operates in the biopharmaceutical industry, focusing on the development of treatments for inflammatory bowel disease.